Biovica has decided to establish a CLIA lab in San Diego, California. A location has been identified and a lease for the premises has been signed. The lab will, after the 510(k) clearance, offer DiviTum®TKa-analysis, to Biovica’s customers in the US.
By operating a CLIA lab, Biovica obtains full control of the selling process including management of reimbursement, ensuring value-based pricing and improved margins. It also allows for direct interactions with physicians and patients – the core DiviTum®TKa customers. In addition, an own lab offers an opportunity to build a sample biobank, an asset in future assay development, and will be an asset for Biovica’s pharma collaborations.
“We see great advantages of operating a Biovica CLIA lab in US. Being in the driver’s seat of the selling and reimbursement processes and in direct contact with physicians and patients will be critical success factors in our commercialization of DiviTum®TKa on the US market. There are several strong reference cases of successful launches of high value diagnostics tests using this model,” said Anders Rylander, CEO of Biovica.
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. Biovica’s choice of San Diego as the preferred location is based on its center of excellence within pharmaceutical and diagnostic research and innovation.